Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) and Catholic Health on Long Island announced a 10-year strategic Care Alliance valued at approximately $500 million. The partnership covers more than 1,300 new technology assets, spanning imaging, diagnostics, AI-enabled tools, cloud and digital solutions across over 40 Catholic Health sites.
The alliance includes system-wide modernization in cardiology, oncology, neurology and women’s health, a multivendor service and maintenance agreement, and deployment of AI-powered platforms such as Imaging 360. About 50% of equipment additions are scheduled within the first three years, with the structure expected to generate capital savings for Catholic Health.
GE HealthCare (NASDAQ:GEHC) and Mayo Clinic announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) collaboration, a theranostics study for patients with advanced prostate cancer. It explores imaging- and biomarker-guided personalization of radioligand therapy, including adapting treatment duration based on individual disease response.
The study uses GE HealthCare’s StarGuide SPECT/CT and MIM Software’s MIM LesionID Pro to link imaging, clinical outcomes and blood biomarkers, aiming to develop predictive markers, support adaptive treatment decisions, expand access to theranostic care and investigate next-generation StarGuide GX SPECT/CT technology at Mayo Clinic’s Rochester campus.
GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026.
Management will host a conference call and live webcast at 8:30 a.m. ET / 7:30 a.m. CT, with materials and replay available on the GE HealthCare investor relations website.
GE HealthCare (Nasdaq: GEHC) declared a cash dividend of $0.035 per share for the second quarter of 2026. The dividend is payable on August 14, 2026 to shareholders of record as of July 24, 2026.
GE HealthCare (GEHC) introduced Allia upgrade pathways to modernize select legacy Innova and Discovery interventional image guiding systems without major construction or full replacement. The upgrades aim to extend room lifetimes, improve workflow efficiency, expand interoperability, and support long-term operational and sustainability goals.
Depending on configuration and regulations, options may include AI-enabled CleaRecon DL, 3DStent, OmnifyXR Interventional Suite, Embo ASSIST AI, Medis Quantitative Flow Ratio, AVVIGO+ IVUS platform, plus Tube Watch and OnWatch Predict services to help reduce unplanned downtime. Upgrades are available where Allia IGS and Allia IGS Pulse are sold.
GE HealthCare (NASDAQ:GEHC) will showcase its latest cloud-enabled enterprise imaging solutions at the SIIM 2026 Annual Meeting, including Genesis Radiology Workspace and Intelerad’s InteleShare platform.
These FDA 510(k)-cleared and cloud-first tools are designed to improve radiology workflows, remote reading, collaboration, and patient care across multi-facility environments.
GE HealthCare (Nasdaq: GEHC) received FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, an AI-enabled auto-contouring software for radiation therapy planning. The clearance includes a Predetermined Change Control Plan (PCCP), supporting faster deployment of future model updates and expanded coverage across more anatomical regions and imaging modalities.
The new version adds an MR Brain model and updated CT Male Pelvis model, is designed to auto-start contouring with minimal user interaction, processes CT and MR images, and integrates into existing treatment planning systems and MIM Workflows.
GE HealthCare (GEHC) is highlighting nuclear medicine innovations at SNMMI 2026, focusing on expanding access, AI-enabled workflows and radiopharmaceutical advances.
Key offerings include Omni Legend PET/CT, StarGuide SPECT/CT, MIM AI software, MINItrace Magni cyclotron, and imaging agents such as Flyrcado, DaTscan, Cerianna and Vizamyl, supporting scalable, precision care.
GE HealthCare (Nasdaq: GEHC) will use the ESTRO 2026 Congress in Stockholm to showcase AI-enabled solutions across radiation therapy, theranostics, and image-guided interventions.
Highlights include the Intelligent Radiation Therapy (iRT) platform, new iRT for Theranostics, advanced MIM oncology software, and BK Medical real-time surgical imaging technologies.
GE HealthCare (Nasdaq: GEHC) is showcasing next-generation SIGNA MR technologies at ISMRM 2026, highlighting AI-powered workflow, helium-free 1.5T systems and advanced 3T scanners. New tools such as SIGNA One, SIGNA Bolt, SIGNA Sprint with Freelium, SIGNA Studio and the investigational MAGNUS prototype aim to accelerate MR research, enhance collaboration and translate innovation into clinical practice.